Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The company reported results that beat expectations and increased its full-year guidance, yet the stock reaction suggested concerns about the sustainability of its growth as membership trends soften.
THE APEX TIMES
THE APEX TIMES
In the most recent trading day, CVS Health (CVS) ended higher, according to market coverage from Yahoo Finance.
THE APEX TIMES
A new market wrap argues Pfizer’s dividend yield is higher than GlaxoSmithKline’s, citing figures of 6.3% versus 4% and using the gap to frame a “better dividend stock” debate.
THE APEX TIMES
The company says new clinical analyses show its Omvoh therapy helped patients achieve corticosteroid-free disease control at one year across difficult inflammatory bowel disease cases, with results reported for both ulcerative colitis and Crohn’s.
THE APEX TIMES
After a roughly 25% gain over six months, Eli Lilly has become the focus of renewed speculation about whether the company could pursue a stock split to make its shares more accessible to smaller investors.
THE APEX TIMES
A healthcare-led rebound lifted Moderna sharply, while BioNTech and Pfizer followed. The move underscores how quickly market flows can shift across sectors, even among companies tied to the same underlying biotechnology platform.
THE APEX TIMES
A fresh comparison of two major U.S. pharma names frames AbbVie’s near-term outlook as increasingly tied to its immunology and inflammation franchise, and Pfizer’s fortunes as dependent on how quickly its next pipeline inflects, particularly in obesity drugs.
THE APEX TIMES
The drugmaker said it will publish its third-quarter 2026 financial results on October 29, 2026, and hold a conference call with the investment community and media the same day.
THE APEX TIMES
Johnson & Johnson trades at a higher earnings multiple than the broader market, a sign investors may be paying up for expectations of faster or more durable growth ahead.
